Pharvaris (NASDAQ:PHVS) President Sells 15,000 Shares

September 10, 2026 by InsiderTrades.com

Key Points

Pharvaris President Peng Lu sold 15,000 shares at an average price of $40.68, generating approximately $610,200 and reducing his direct ownership by 18.71% to 65,179 shares.
Pharvaris reported positive Phase 3 CHAPTER-3 results for extended-release deucrictibant, with the trial meeting its primary and secondary endpoints for preventing hereditary angioedema attacks. Regulatory applications are expected to begin in the first half of 2027.
Analyst sentiment remains favorable, with 12 Buy ratings and a consensus “Moderate Buy” recommendation; the average price target is $59.21 versus the stock’s reported $37.74 opening price. However, regulatory approval and commercial execution remain key risks.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) President Peng Lu sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total value of $610,200.00. Following the transaction, the president directly owned 65,179 shares in the company, valued at $2,651,481.72. The trade was a 18.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Peng Lu also recently made the following trade(s):

On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total transaction of $10,200.00.

Pharvaris Stock Performance

Shares of PHVS opened at $37.74 on Thursday. The stock has a 50 day moving average price of $34.93 and a two-hundred day moving average price of $31.27. The firm has a market capitalization of $2.47 billion, a P/E ratio of -12.37 and a beta of -2.33. Pharvaris N.V. has a 52 week low of $20.65 and a 52 week high of $43.25.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities analysts forecast that Pharvaris N.V. will post -3.15 earnings per share for the current year.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. venBio Partners LLC bought a new position in shares of Pharvaris in the second quarter worth $160,569,809. Wellington Management Group LLP bought a new position in Pharvaris in the 3rd quarter worth about $43,282,000. 5AM Venture Management LLC bought a new position in Pharvaris in the 2nd quarter worth about $27,581,008. California State Teachers Retirement System increased its position in shares of Pharvaris by 3,210.1% during the second quarter. California State Teachers Retirement System now owns 799,490 shares of the company's stock valued at $27,646,000 after buying an additional 775,337 shares during the period. Finally, Paradigm Biocapital Advisors LP increased its position in shares of Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock valued at $45,796,000 after buying an additional 772,583 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PHVS. Morgan Stanley lifted their price target on Pharvaris from $46.00 to $62.00 and gave the stock an "overweight" rating in a report on Wednesday. Citizens Jmp upped their price objective on Pharvaris from $75.00 to $79.00 and gave the company a "market outperform" rating in a research note on Wednesday. Guggenheim raised their target price on Pharvaris from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Leerink Partners lifted their target price on Pharvaris from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pharvaris currently has a consensus rating of "Moderate Buy" and an average price target of $59.21.

Read Our Latest Research Report on PHVS

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

Positive Sentiment: Pharvaris reported that its pivotal Phase 3 CHAPTER-3 trial of extended-release deucrictibant met its primary and all secondary efficacy endpoints, showing statistically significant and clinically meaningful prevention of HAE attacks. The results are intended to support regulatory applications planned to begin in the first half of 2027. Pharvaris CHAPTER-3 topline data
Positive Sentiment: The CHAPTER-3 success, combined with earlier positive Phase 3 results for on-demand deucrictibant, strengthens Pharvaris’ potential to offer oral options for both prevention and treatment of HAE attacks. Analysts said the data could help the company capture market share in the HAE market. Pharvaris could gain HAE market share
Positive Sentiment: RBC raised its price target to $62 from $52 and maintained an Outperform rating, while Citizens JMP increased its target to $79 from $75 with a Market Outperform rating. HC Wainwright also reaffirmed Buy with a $60 target, indicating broad analyst confidence in the program’s commercial potential.
Positive Sentiment: A Seeking Alpha analysis maintained a “Strong Buy” view, citing the Phase 3 wins and the upcoming regulatory decision, or PDUFA event, for deucrictibant. Pharvaris Strong Buy analysis
Neutral Sentiment: Despite the favorable data, Pharvaris remains a clinical-stage company. Regulatory approval, commercial execution, and the ability to compete with existing HAE therapies remain important uncertainties; RBC continued to characterize the stock as carrying speculative risk.
Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The transaction may create a modest overhang, although it does not change the clinical outlook.

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.